Meeting Materials

<strong>Introduction:</strong><br>Central nervous system (CNS) involvement is a rare event in acute myeloid leukemia (AML). The exact incidence of CNS disease in AML is unknown as routine diagnostic lumbar puncture is not performed.

<strong>Introduction:</strong><br>Patients with polycythemia vera (PV) are treated with periodic therapeutic phlebotomy (TP) alone or in combination with cytoreductive therapies (CRT) to maintain hematocrit (HCT) <‚Äâ45%, per NCCN and ELN guidelines.

<strong>Introduction:</strong><br>Acute promyelocytic leukemia (APL) is rare and accounts for only 5-8% of acute myeloid leukemia and is characterized by t(15;17).Variant APL caused by a variant translocation t(11,17) constitutes only 0.8% of cases of APL and poses a diagnostic

<strong>Introduction:</strong><br>Usually, Thrombocytopenic purpura is seen late in the course of Hodgkin’s disease and usually results from bone marrow failure.

#REF!

#REF!

<strong>Introduction:</strong><br>Novel oncolytic agents, including the first-in-class BTKi ibrutinib, have transformed CLL/SLL and MCL treatment.

<strong>Introduction:</strong><br>Clinical trials are biased towards the younger and fitter. Therefore TRIATLON compared a real-world (RW) population of MM pts.

<strong>Background:</strong><br>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, debilitating condition of the hemopoietic stem cells. The morbidity and mortality depend upon the severity of hemolysis, bone marrow failure, and thrombophilia.

<strong>Introduction:</strong><br>Castleman disease (CD) is a group of rare, heterogeneous lymphoproliferative disorders that share histological features and have varying grades of severity.

<strong>Introduction:</strong><br>Classical Hodgkin’s Lymphoma (cHL) presenting as cholestatic or obstructive jaundice often has a complicated clinical course.

<p><strong>Introduction:</strong><br />

<strong>Introduction:</strong><br>Leukemia patients who are Jehovah’s witnesses can be challenging to treat from a hematologic malignancy standpoint, as they are not permitted to accept blood or blood products.

<strong>Introduction:</strong><br>Patients with

<strong>Introduction:</strong><br>Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Epcoritamab is a subcutaneously administered bispecific antibody that induces killing of malignant CD20

<strong>Introduction:</strong><br>Oral oncolytics offer advantages over chemotherapy, but oncology patients may face treatment compliance challenges. Previous studies have shown patient support programs (PSPs) can improve treatment compliance.

<strong>Introduction:</strong><br>Multiple Myeloma (MM) cells show resistance to standard therapies due to overexpression of the transport protein, Exportin 1. Selinexor is a novel drug that targets the Exportin 1 protein on these cells.

<strong>Introduction:</strong><br>More tolerable, readily available treatment options are needed for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) to induce deep, durable responses.

<strong>Introduction:</strong><br>Up to 50% of newly diagnosed multiple myeloma patients present with acute renal injury secondary to the neoplasia, which is produced by multifactorial events, being tubular damage and direct toxicity of tubular cells the most-understood mechanis

<strong>Introduction:</strong><br>Relapsed or refractory (R/R) follicular lymphoma (FL) has a poor prognosis and is associated with less-durable responses following each additional line of treatment. Although combination rituximab and lenalidomide (R

<strong>Introduction:</strong><br>Lymphoma is the sixth most common cancer in the world. Hodgkin's lymphoma is the third most common lymphoma in developing countries and the second most common lymphoma in industrialized countries.

<strong>Introduction:</strong><br>The 4-year survival rate is only 55% (Sehn et al,

<strong>Introduction:</strong><br>β-Thalassemia is an inherited genetic disorder characterized by an imbalance in the α/β globin chain ratio.

<p><strong>Introduction:</strong><br />

<strong>Introduction:</strong><br>Ibrutinib and acalabrutinib are both Bruton’s tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

<strong>Introduction:</strong><br>Treatment of B-cell malignancies has been improved by effective inhibitors of B-cell receptor signaling, such as the first-generation Bruton tyrosine kinase inhibitor (BTKi), ibrutinib.

<strong>Introduction:</strong><br>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. Acquired HLH can be triggered by viral infections, with Epstein-Barr virus (EBV) among the most common etiologies.

<strong>Introduction:</strong><br>Despite therapeutic advances, patients with relapsed or refractory (R/R) DLBCL have a dire prognosis.

<strong>Introduction:</strong><br>Histiocytic sarcoma (HS) is an extremely rare non-Langerhans histiocytic neoplasm that can present as unifocal or multifocal disease.

<strong>Introduction:</strong><br>Multiple myeloma (MM) is the second most common hematological malignancy worldwide. The treatment of MM is induction therapy followed by an autologous stem cell transplant (ASCT).

<strong>Introduction:</strong><br>Myeloid sarcoma and leukemia cutis are extramedullary (EM) manifestations of acute myeloid leukemia (AML).

<strong></strong><br><br><strong>Methods:</strong><br>This retrospective cohort study included adult patients with chronic myelogenous leukemia (CML), ovarian cancer or prostate cancer initiating oral oncolytics between 3/1/19 and 3/1/2021.

<strong>Introduction:</strong><br>Indolent non-Hodgkin lymphoma (iNHL) is characterized by multiple relapses, with patients experiencing increasingly shorter progression-free intervals.

<strong>Introduction:</strong><br>Haploidentical stem cell transplantation (Haplo SCT) is a curative option in patients with hematological malignancies. For patients older than age 70, SCT from matched donors (sibling/unrelated) has been reported in several studies.

<strong>Introduction:</strong><br>Magrolimab is a monoclonal antibody that blocks CD47, a “don’t eat me” signal overexpressed on cancer cells.

<strong>Introduction:</strong><br>Multiple myeloma (MM) arises from neoplastic proliferation of plasma cells whose survival is potentiated by the bone marrow (BM) microenvironment.

<strong>Introduction:</strong><br>Skeletal-related events (SREs) are common among patients with Multiple Myeloma (MM), causing increased disease burden and mortality.

<strong>Introduction:</strong><br>Recent clinical trials have demonstrated the prognostic importance of the F18-fluorodeoxyglucose interim-PET scan in early-stage classical Hodgkin lymphoma (HL); however, the role of end-of-treatment (EOT)-PET remains poorly explored.

<strong>Introduction:</strong><br>Leptomeningeal disease (LMD) is a condition whereby cancer cells metastasize to the arachnoid and pia mater, from where they gained access to the cerebrospinal fluid and caused various neurological complications.

<strong>Introduction:</strong><br>Achievement of minimal residual disease negativity (MRD–) status in multiple myeloma (MM) is associated with improved progression-free survival (PFS) and overall survival.

<strong>Introduction:</strong><br>MLAT lymphoma is a rare form of non-Hodgkin's malignant lymphoma that affects B lymphocytes and develops at the expense of lymphoid tissue associated with mucous membranes, but also in a rarer way at the level of a lymph node, it seems to h

<strong>Introduction:</strong><br>Magrolimab (Hu5F9-G4) is an antibody blocking CD47, a macrophage immune checkpoint and “don’t eat me” signal on cancer cells, that eliminates leukemia stem cells by inducing tumor phagocytosis.

<strong>Introduction:</strong><br>Carfilzomib (CFZ) is a proteasome inhibitor indicated in Multiple Myeloma patients who have relapsed after subsequent lines of treatment or have become refractory to first-line therapy.

<p><strong>Introduction:</strong><br />

<strong>Introduction:</strong><br>Acute myeloid leukemia (AML) is an aggressive clonal hematopoietic malignancy of myeloid cells associated with limited outcomes for patients who are ineligible for intensive chemotherapy due to age or comorbidities.

<strong>Introduction:</strong><br>The BEAM (BCNU/Carmustine, Etoposide, Cytarabine, Melphalan) regimen has historically been favored as the conditioning treatment of choice for patients with relapsed or refractory lymphoma undergoing autologous stem cell transplant (ASCT).

<strong>Introduction:</strong><br>Collection of “real world“ clinical data in patients with hematologic malignancies by special registries becomes more and more important due to limiting recruitment to clinical trials by entry criteria.

<strong>Introduction:</strong><br>The advent of tyrosine kinase inhibitors (TKI) has significantly improved the survival of patients with chronic myeloid leukemia (CML).

<strong>Introduction:</strong><br>High-grade B cell lymphomas are rare, aggressive diffuse Large B cell lymphomas (DBCLs) with genetic translocations involving MYC plus BCL2 and/or BCL6 (double or triple hit).

<strong>Introduction:</strong><br>Thrombotic thrombocytopenic purpura (TTP) is a very rare complication of acute pancreatitis. Acute pancreatitis can develop from TTP, but TTP as a consequence of pancreatitis is extremely rare.

<strong>Introduction:</strong><br>COVID-19 has impacted several areas of oncology patient care, most notably the reduction of patient visits for treatments. Standard treatment of multiple myeloma (MM) involves a combination of intravenous (IV) and oral therapies.

<strong>Introduction:</strong><br>Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of peripheral T-cell lymphoma (PTCL). We encountered a rare case of a patient who presented with bilateral neck masses.

<strong>Introduction:</strong><br>Mantle cell lymphomas are a category of B-cell Non-Hodgkins lymphomas which have an aggressive clinical course. On Immunohistochemistry (IHC) evaluation, these usually show positivity for CD5, Cyclin D1 and SOX 11.

<strong>Introduction:</strong><br>Patients with relapsed indolent NHL (iNHL) have limited standard treatment options. Lenalidomide combined with rituximab (R

<strong>Introduction:</strong><br>The anti-CD38 antibody Isa in combination with Kd is approved in various countries for patients (pts) with relapsed MM after ‚â•1 prior therapy, based on primary interim analysis (IA) of the Phase 3 IKEMA study (NCT03275285).

<strong>Introduction:</strong><br>SC Isa delivery would optimize convenience of administration.